For its part, everolimus (Afinitor, Novartis Europharm Limited, Ireland), which is an inhibitor of the mTORC1 complex, was approved by the FDA in 2009 for patients with hormone-receptor-positive, HER2-negative advanced breast cancer in combination with exemestane (Exemestane Sandoz, Sandoz Farmacéutica, Madrid, Spain), which is a steroid aromatase inhibitor. This evidence concerns the gene NR4A1 and breast carcinoma.